Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 62.8 CHF 1.45% Market Closed
Market Cap: 1B CHF
Have any thoughts about
Cosmo Pharmaceuticals NV?
Write Note

Relative Value

The Relative Value of one COPN stock under the Base Case scenario is 143.57 CHF. Compared to the current market price of 62.8 CHF, Cosmo Pharmaceuticals NV is Undervalued by 56%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COPN Relative Value
Base Case
143.57 CHF
Undervaluation 56%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
13
Median 3Y
10
Median 5Y
13.5
Industry
2.5
Forward
4
vs History
55
vs Industry
0
Median 3Y
44.4
Median 5Y
16.9
Industry
21.9
Forward
8.4
vs History
74
vs Industry
13
Median 3Y
33.1
Median 5Y
29.4
Industry
16.5
vs History
vs Industry
7
Median 3Y
-6.8
Median 5Y
-15.9
Industry
23.6
vs History
60
vs Industry
32
Median 3Y
2.1
Median 5Y
2.4
Industry
2.1
vs History
88
vs Industry
14
Median 3Y
9.2
Median 5Y
12.7
Industry
2.6
Forward
3.5
vs History
96
vs Industry
12
Median 3Y
17.2
Median 5Y
23.2
Industry
5.2
vs History
82
vs Industry
9
Median 3Y
24.5
Median 5Y
30.3
Industry
13.3
Forward
5.3
vs History
84
vs Industry
5
Median 3Y
38.1
Median 5Y
47.3
Industry
16.6
Forward
5.7
vs History
74
vs Industry
16
Median 3Y
30.4
Median 5Y
23.1
Industry
15.6
vs History
74
vs Industry
9
Median 3Y
55.8
Median 5Y
29.6
Industry
19.1
vs History
58
vs Industry
40
Median 3Y
1.6
Median 5Y
2.3
Industry
1.9

Multiples Across Competitors

COPN Competitors Multiples
Cosmo Pharmaceuticals NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Cosmo Pharmaceuticals NV
SIX:COPN
1B CHF 5.7 14.3 8.9 10.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average P/E: 30.1
14.3
8 155%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top